InflaRx N.V. (NASDAQ:IFRX) Short Interest Up 26.7% in December

InflaRx N.V. (NASDAQ:IFRX) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 2,745,086 shares, a growth of 26.7% from the November 30th total of 2,166,680 shares. Based on an average daily volume of 847,910 shares, the short-interest ratio is currently 3.2 days. Approximately 4.9% of the company’s shares are short sold. Approximately 4.9% of the company’s shares are short sold. Based on an average daily volume of 847,910 shares, the short-interest ratio is currently 3.2 days.

Wall Street Analyst Weigh In

Several analysts have issued reports on IFRX shares. Guggenheim boosted their target price on shares of InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Leerink Partnrs lowered InflaRx from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Monday. Finally, Wall Street Zen downgraded InflaRx from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.50.

InflaRx Stock Performance

IFRX opened at $1.02 on Wednesday. The stock has a market cap of $68.48 million, a price-to-earnings ratio of -1.50 and a beta of 1.46. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.77. The stock has a fifty day moving average price of $1.21 and a 200 day moving average price of $1.13.

InflaRx (NASDAQ:IFRX) last issued its earnings results on Monday, November 10th. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. As a group, sell-side analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of InflaRx

A number of institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC grew its position in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares in the last quarter. 683 Capital Management LLC lifted its stake in shares of InflaRx by 26.8% in the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares during the last quarter. Woodline Partners LP bought a new stake in InflaRx in the first quarter worth $766,000. Concurrent Investment Advisors LLC bought a new stake in InflaRx in the second quarter worth $65,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in InflaRx by 158.3% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after buying an additional 91,927 shares during the last quarter. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.